Investor Relations
Stay informed about Lytix Biopharma's financial performance, corporate governance, and strategic initiatives driving value for our shareholders.
Investor PortalFinancial Reports
Annual & quarterly reports
Stock Information
Share price & trading
Events & Calendar
Upcoming presentations
Corporate Governance
Board & policies
Latest Press Releases
Stay updated with our latest corporate announcements.
January 14, 2026
Lytix Biopharma Announces Positive Interim Data from NeoLIPA Phase 2 Study
Strong tumor response rates observed in resectable melanoma patients receiving combination therapy.
January 10, 2026
Lytix Biopharma Reports Q4 2025 Financial Results
Company maintains strong cash position to support pipeline advancement through key milestones.
December 18, 2025
Lytix Biopharma Presents at J.P. Morgan Healthcare Conference
Management presented company strategy and pipeline updates to institutional investors.
December 5, 2025
Partner Verrica Reports Positive Phase 2 Results for VP-315 in BCC
51% complete response rate and 97% clinical response rate demonstrated in basal cell carcinoma study.
November 20, 2025
Lytix Biopharma Appoints New Chief Medical Officer
Seasoned oncology executive joins leadership team to advance clinical development programs.
Questions for our IR team?
For investor inquiries, please contact our investor relations team directly.